Literature DB >> 11015683

Transporter-mediated permeation of drugs across the blood-brain barrier.

I Tamai1, A Tsuji.   

Abstract

Drug distribution into the brain is strictly regulated by the presence of the blood-brain barrier (BBB) that is formed by brain capillary endothelial cells. Since the endothelial cells are connected to each other by tight junctions and lack pores and/or fenestrations, compounds must cross the membranes of the cells to enter the brain from the bloodstream. Therefore, hydrophilic compounds cannot cross the barrier in the absence of specific mechanisms such as membrane transporters or endocytosis. So, for efficient supply of hydrophilic nutrients, the BBB is equipped with membrane transport systems and some of those transporter proteins have been shown to accept drug molecules and transport them into brain. In the present review, we describe mainly the transporters that are involved in drug transfer across the BBB and have been molecularly identified. The transport systems described include transporters for amino acids, monocarboxylic acids, organic cations, hexoses, nucleosides, and peptides. Most of these transporters function in the direction of influx from blood to brain; the presence of efflux transporters from brain to blood has also been demonstrated, including P-glycoprotein, MRPs, and other unknown transporters. These efflux transporters seem to be functional for detoxication and/or prevention of nonessential compounds from entering the brain. Various drugs are transported out of the brain via such efflux transporters, resulting in the decrease of CNS side effects for drugs that have pharmacological targets in peripheral tissues or in the reduction of efficacy in CNS because of the lower delivery by efflux transport. To identify the transporters functional at the BBB and to examine the possible involvement of them in drug transports by molecular and physiological approaches will provide a rational basis for controlling drug distribution to the brain. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015683     DOI: 10.1002/1520-6017(200011)89:11<1371::aid-jps1>3.0.co;2-d

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  63 in total

1.  Computation of log BB values for compounds transported through carrier-mediated mechanisms using in vitro permeability data from brain microvessel endothelial cell (BMEC) monolayers.

Authors:  Helen H Usansky; Patrick J Sinko
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

Review 2.  Mitochondrial energy metabolism in neurodegeneration associated with methylmalonic acidemia.

Authors:  Daniela R Melo; Alicia J Kowaltowski; Moacir Wajner; Roger F Castilho
Journal:  J Bioenerg Biomembr       Date:  2011-02       Impact factor: 2.945

Review 3.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

4.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 5.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

Review 6.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

7.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

8.  In vitro P-glycoprotein activity does not completely explain in vivo efficacy of novel centrally effective oxime acetylcholinesterase reactivators.

Authors:  Mary Beth Dail; Edward Caldwell Meek; Howard Wayne Chambers; Janice Elaine Chambers
Journal:  Drug Chem Toxicol       Date:  2018-05-03       Impact factor: 3.356

9.  Biochemistry and bioenergetics of glutaryl-CoA dehydrogenase deficiency.

Authors:  S W Sauer
Journal:  J Inherit Metab Dis       Date:  2007-09-21       Impact factor: 4.982

10.  Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea.

Authors:  Banmeet S Anand; Ashim K Mitra
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.